>북미 CRISPR 유전자 검출 및 진단 시장, 클래스별(클래스 1- 다중 효과 단백질 및 클래스 2- 단일 CrRNA 결합 단백질), 제품 및 서비스(제품 및 서비스), 응용 분야(생물의학 진단, 게놈 엔지니어링, 약물 발견, 농업 응용 분야 및 기타), 워크플로(샘플 준비, 사전 증폭, CrRNA, Cas 효소 및 감지), 최종 사용자(병원, 진단 센터, 생명공학 회사, 학술 및 연구 기관 및 기타), 유통 채널(직접 입찰, 소매 판매) 산업 동향 및 2029년까지의 예측
시장 정의 및 통찰력
CRISPR는 규칙적으로 간격을 둔 짧은 회문 반복으로 클러스터링되며 게놈 편집 도구로, 연구자들이 DNA 시퀀스를 변경하고 유전자 기능을 쉽게 수정할 수 있도록 합니다. 유전적 결함을 교정하고 질병의 확산을 치료하고 예방하는 것을 포함하여 많은 잠재적인 응용 분야가 있습니다. CRISPR 기반 진단은 감염성 및 비감염성 질병의 핵산 기반 바이오마커를 감지하고 유전적 질병을 탐지하는 것과 같은 많은 생물의학적 응용 분야에 사용되었습니다. CRISPR의 분석 키트는 Cas9라는 단백질과 특정 유전 코드를 가진 핵산 분자의 문자열인 가이드 RNA의 두 가지 구성 요소로 구성됩니다.
이 CRISPR-Cas9 시스템은 포유류 세포에서 사용하도록 수정되었습니다. 우리는 프레임시프트 돌연변이를 비동족 말단 접합(NHEJ)을 통해 도입하여 관심 유전자에 특정한 가이드 시퀀스(sgRNA)를 도입하여 특정 유전자를 녹아웃하거나 녹인 돌연변이를 생성할 수 있습니다.
CRISPR-Cas 9 시스템은 유전자 및 세포 치료의 진단 및 서비스 범위를 확대했습니다. 제약 회사는 새로운 제품을 개발하기 위해 R&D에 많은 투자를 하고 있으며, 유전자 및 세포 치료제가 초기 개발에 돌입하고 있습니다. 투자하는 시장 참여자는 심각한 도움이 필요한 환자를 위해 안전하고 효과적인 치료법을 생산할 수 있습니다.
북미 CRISPR 유전자 검출 및 진단은 지원적이며 증상의 심각성을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 CRISPR 유전자 검출 및 진단 시장이 2022년에서 2029년까지의 예측 기간 동안 19.6%의 CAGR로 성장할 것이라고 분석합니다.
|
보고서 메트릭 |
세부 |
|
예측 기간 |
2022년부터 2029년까지 |
|
기준 연도 |
2021 |
|
역사적 연도 |
2020 (2019-2014까지 사용자 정의 가능) |
|
양적 단위 |
수익은 백만 달러, 가격은 미화로 표시됨 |
|
다루는 세그먼트 |
분류별(분류 1- 다중 효과 단백질 및 분류 2- 단일 CrRNA 결합 단백질), 제품 및 서비스(제품 및 서비스), 응용 분야(생물의학 진단, 게놈 엔지니어링, 약물 발견, 농업 응용 분야 및 기타), 워크플로(샘플 준비, 사전 증폭, CrRNA, Cas 효소 및 감지), 최종 사용자(병원, 진단 센터, 생명 공학 회사, 학술 및 연구 기관 및 기타) 유통 채널(직접 입찰, 소매 판매) |
|
적용 국가 |
미국, 캐나다, 멕시코 |
|
시장 참여자 포함 |
GenScript, OriGene Technologies, Inc., Applied StemCell, GeneCopoeia, Inc., Agilent Technologies, Inc., Synthego, BioVision Inc., Hera Biolabs, Cellecta, Inc., New England Biolabs, 10x Genomics, addgene CasTag Biosciences, Merck KGaA, Integrated DNA Technologies, Inc. (A subsidiary of Danaher), Thermo Fisher Scientific Inc. among others |
North America CRISPR Gene Detection and Diagnostic Market Dynamics
Drivers
- Rise in prevalence and incidence of chronic diseases
Chronic diseases are common health conditions, where one in three the adults suffer from chronic conditions. Chronic diseases have affected the health and quality of life of many citizens.
CRISPR is abbreviated as clustered regularly interspaced short palindromic repeats. In recent years, CRISPR has become a commanding tool for gene editing, which is used to alter the specific sequences of DNA in a cell. CRISPR has important use in the research and treatment of Huntington’s disease, muscular dystrophy, cancer and high cholesterol.
For instance,
- In 2021, the data by NORD - National Organization for Rare Disorders, Inc. stated the diagnosed incidence of Duchenne Muscular Dystrophy (DMD). The Duchenne Muscular Dystrophy (DMD) is a frequent genetic condition, which affects 1 in 3,500 male births worldwide
- Rise In Investment In Research And Development
Gene editing technologies, such as the CRISPR-Cas 9 system, have extended the scope of diagnostics and services in gene and cell therapies. Pharmaceutical companies invest heavily in R&D to develop new products, with a surge of gene and cell therapy agents entering early development. The market players investing would allow to achieve the goal of producing safe and effective treatments for patients in serious need.
For instance,
- In February 2022, Synthego had raised USD 200 million as an investment for research and development to boost the development of CRISPR-Based Medicines from early-phase research to the clinic. Synthego will use the investment amount from Series E finance to accelerate the creation of CRISPR diagnostics and services
Availability of funding for CRISPR gene diagnostics
CRISPR gene diagnostics and research are funded by the National Institute of Health (NIH) budget. The private sector also funds the CRISPR gene detection and research, but such investment generally occurs later, during the testing and development phase, then during initial basic research. With genome editing being such a new field, an unbiased governmental body must supervise them; the FDA is cautious and thorough, but they are endlessly struggling for funding, making a long-term investment that aligns the payment with the potential future beneficiaries., will further enhance the growth of the CRISPR gene detection and diagnostic market.
Furthermore, advancement in CRISPR gene diagnostics, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the CRISPR gene detection market. Other factors such as increase in the demand for effective therapies and rising awareness about the timely diagnosis and will positively impact the CRISPR gene detection and diagnostic market's growth rate. Additionally, high disposable income, rising number of chronic diseases, changing lifestyle will result in the expansion of the CRISPR gene detection and diagnostic market.
Opportunities
- The rise in healthcare expenditure
Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.
- Strategic initiative by market players
The demand for CRISPR gene detection and diagnosis has increased the demand in the U.S. and owing to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
For instance,
- In May 2021, Horizon Discovery Ltd. extended the gene modulation portfolio with the first synthetic single guide RNA and patent pending dcas9 repressor for CRISPR interference in Waltham. The expansion of the portfolio had increased the sales and revenue of the synthetic guide RNA portfolio across the U.S. and the U.K. region and had increased the collaboration with market players
Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the CRISPR gene detection and diagnostic market in the forecast period of 2022-2029. Also, high unmet need of current and developments in healthcare technology will escalate the growth rate of the CRISPR gene detection and diagnostic market in future.
Restraints/Challenges
However, high cost of CRISPR diagnostics and risks faced while using the CRISPR diagnostics will impede the growth rate of CRISPR gene detection and diagnostic market. Additionally, the risks incurred while using the MRI devices will hinder the CRISPR gene detection and diagnostic market growth. The lack of skilled expertise and regulations will further challenge the market in the forecast period mentioned above.
- Rise in cost of CRISPR based diagnostics
The vast potential of CRISPR based therapeutics comes with a cost tag. Maximum genome editing therapies require an increased amount of time for development and production, and hence the rise in cost occurs. Besides, the assay kits and medications related to CRISPR gene detection and diagnostic are applicable to large section of population. These costs are pushed on patients. Therefore, the present high cost is expected to show a descending trend in the future.
For instance,
- In July 2021, according to Integrated DNA Technologies, Inc., the first commercially available CRISPR-based diagnostic assay for SARS-CoV-2 including reverse transcription LAMP (RT-LAMP) as pre-amplification is currently available at USD 30.15 per reaction
The CRISPR gene detection and diagnostic market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on CRISPR gene detection and diagnostic market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
According to a study by Globocan. In 2020, breast cancer had high incidence of cases, around 11.7%, followed by lung cancer which is 11.40%, colorectum cancer which is 10.00%, and cervix uteri and oesophagus cancer having less number of incident cases.
CRISPR gene detection and diagnostic market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on the CRISPR Gene Detection and Diagnostic Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.
Recent Development
- 2020년 8월, SHERLOCK BIOSCIENCES는 Dartmouth-Hitchcock Health와 협력하여 Sars-CoV-2에 대한 SHERLOCK 진단 키트의 임상 시험을 실시한다고 발표했습니다. 이 키트는 미국 식품의약국(FDA)의 긴급 사용 허가(EUA)로부터 긴급 승인을 받았습니다.
북미 CRISPR 유전자 검출 및 진단 시장 범위
CRISPR 유전자 검출 및 진단 시장은 클래스, 제품 및 서비스, 애플리케이션, 워크플로, 최종 사용자, 유통 채널의 6개 세그먼트를 기준으로 세분화됩니다. 이러한 세그먼트 간의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 핵심 시장 애플리케이션을 식별하기 위한 전략적 결정을 내리는 데 도움이 되는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 됩니다.
수업
- 클래스 1 - 다중 효과 단백질
- 2등급 - 단일 CrRNA 결합 단백질
CRISPR 유전자 검출 및 진단 시장은 클래스를 기준으로 클래스 1(다중 효과 단백질)과 클래스 2(단일 CrRNA 결합 단백질)로 구분됩니다.
제품 및 서비스
- 제품
- 서비스
CRISPR 유전자 검출 및 진단 시장은 제품과 서비스를 기준으로 다음과 같이 세분화됩니다.
애플리케이션
- 생물의학 진단
- 게놈 엔지니어링
- 약물 발견
- 농업 응용 프로그램
- 기타
CRISPR 유전자 검출 및 진단 시장은 응용 분야를 기준으로 생물의학 진단, 유전체 공학, 신약 발견, 농업 응용 분야 등으로 세분화됩니다.
작업 흐름
- 샘플 준비
- 사전 증폭
- 크립RNA
- 카스 효소
- 감지
워크플로우를 기준으로 CRISPR 유전자 검출 및 진단 시장은 샘플 준비, 사전 증폭, CrRNA, Cas 효소 및 감지로 구분됩니다.
최종 사용자
- 병원
- 진단 센터
- 생명공학 회사
- 학술 및 연구 기관
- 기타
최종 사용자를 기준으로 CRISPR 유전자 검출 및 진단 시장은 병원, 진단 센터, 생명공학 기업, 학술 및 연구 기관 등으로 세분화됩니다.
유통 채널
- 직접 입찰
- 소매 판매
유통 채널을 기준으로 CRISPR 유전자 검출 및 진단 시장은 직접 입찰과 소매 판매로 구분됩니다.
CRISPR 유전자 검출 및 진단 시장 지역 분석/통찰력
북미 CRISPR 유전자 검출 및 진단 시장을 분석하고, 위에 언급된 대로 지역, 계층, 제품 및 서비스, 응용 프로그램, 워크플로, 최종 사용자, 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
CRISPR 유전자 검출 및 진단 시장 보고서에서 다루는 국가는 미국, 캐나다, 멕시코입니다.
미국은 의료비 지출 증가로 인해 CRISPR 유전자 검출 및 진단 시장을 장악하고 있습니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제의 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 북미 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 CRISPR 유전자 검출 및 진단 시장 점유율 분석
북미 CRISPR 유전자 검출 및 진단 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 북미 지역, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우위가 있습니다. 제공된 위의 데이터 포인트는 CRISPR 유전자 검출 및 진단 시장과 관련된 회사의 초점에만 관련이 있습니다.
CRISPR 유전자 검출 및 진단 시장의 주요 기업으로는 GenScript, OriGene Technologies, Inc., Applied StemCell, GeneCopoeia, Inc., Agilent Technologies, Inc., Synthego, BioVision Inc., Hera Biolabs, Cellecta, Inc., New England Biolabs, 10x Genomics, addgene CasTag Biosciences, Merck KGaA, Integrated DNA Technologies, Inc. (Danaher의 자회사), Thermo Fisher Scientific Inc. 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASS SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 INTELLECTUAL PROPERTY LANDSCAPE (PATENT LANDSCAPE)
6 EPIDEMIOLOGY
7 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: REGULATORY SCENARIO
8 PIPELINE ANALYSIS FOR NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, OF CRISPR DIAGNOSTICS
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES
9.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT
9.1.3 AVAILABILITY OF FUNDING FOR CRISPR GENE DIAGNOSTICS
9.1.4 RISE IN GMP-CERTIFICATION APPROVALS FOR CRISPR GENE DIAGNOSTIC
9.1.5 RISE IN CLINICAL TRIALS FOR CRISPR BASED DIAGNOSTICS
9.2 RESTRAINTS
9.2.1 RISE IN COST OF CRISPR BASED DIAGNOSTICS
9.2.2 RISKS FACED WHILE USING CRISPR DIAGNOSIS
9.2.3 ETHICAL CONCERNS RELATED TO CRISPR GENE DETECTION AND DIAGNOSTIC RESEARCH
9.2.4 AVAILABILITY OF ALTERNATIVES
9.3 OPPORTUNITIES
9.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
9.3.2 RISE IN HEALTHCARE EXPENDITURE
9.3.3 EMERGENCE OF TECHNOLOGICAL ADVANCEMENTS IN CRISPR BASED DIAGNOSTICS
9.4 CHALLENGES
9.4.1 LACK OF SKILLED PROFESSIONALS REQUIRED FOR CRISPR DIAGNOSTICS
9.4.2 STRINGENT REGULATIONS
10 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS
10.1 OVERVIEW
10.2 CLASS-2 SINGLE CRRNA-BINDING PROTEIN
10.2.1 BIOMEDICAL DIAGNOSTICS
10.2.2 AGRICULTURAL APPLICATIONS
10.2.3 GENOME ENGINEERING
10.2.4 DRUG DISCOVERY
10.2.5 OTHERS
10.3 CLASS-1 MULTIPLE EFFECTOR PROTEINS
11 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES
11.1 OVERVIEW
11.2 PRODUCTS
11.2.1 ASSAY KITS
11.2.1.1 SGRNA KIT
11.2.1.2 GENOMIC DETECTION KIT
11.2.1.3 OTHERS
11.2.2 PROTEINS
11.2.2.1 CAS9
11.2.2.2 CPF1
11.2.2.3 OTHERS
11.2.3 PLASMID AND VECTOR
11.2.4 LIBRARY
11.2.5 CONTROL KITS
11.2.6 DELIVERY SYSTEM PRODUCTS
11.2.7 DESIGN TOOLS
11.2.8 GENOMIC RNA
11.2.9 HDR BLOCKERS
11.2.9.1 AZIDOTHYMIDINE
11.2.9.2 TRIFLUOROTHYMIDINE
11.2.9.3 OTHERS
11.2.9.4 OTHERS
11.3 SERVICES
11.3.1 G-RNA DESIGN
11.3.2 CELL LINE ENGINEERING
11.3.3 MICROBIAL GENE EDITING
11.3.4 DNA SYNTHESIS
11.3.5 OTHERS
12 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 BIOMEDICAL DIAGNOSTICS
12.2.1 CANCER
12.2.2 BLOOD DISORDERS
12.2.3 HEREDITARY DISORDERS
12.2.4 MUSCULAR DYSTROPHY
12.2.5 AIDS
12.2.6 NEURODEGENERATIVE CONDITION
12.2.7 OTHERS
12.3 AGRICULTURAL APPLICATIONS
12.4 GENOME ENGINEERING
12.4.1 CELL LINE ENGINEERING
12.4.2 HUMAN STEM CELLS
12.5 DRUG DISCOVERY
12.6 OTHERS
13 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW
13.1 OVERVIEW
13.2 CRRNA
13.3 CAS ENZYME
13.4 PRE-AMPLIFICATION
13.4.1 PCR
13.4.2 LAMP
13.4.3 RPA
13.5 SAMPLE PREPARATION
13.6 SENSING
13.6.1 FLUORESCENT PROBES
13.6.2 COLORIMETRIC
14 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER
14.1 OVERVIEW
14.2 BIOTECHNOLOGY COMPANIES
14.3 ACADEMIC AND RESEARCH INSTITUTES
14.4 DIAGNOSTIC CENTERS
14.5 HOSPITALS
14.6 OTHERS
15 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
16 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 THERMO FISHER SCIENTIFIC INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 MERCK KGA
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 AGILENT TECHNILOGIES, INC
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER)
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 GENSCRIPT
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 COMPANY SHARE ANALYSIS
19.5.4 PRODUCT PORTFOLIO
19.5.5 RECENT DEVELOPMENT
19.6 10 X GENOMICS
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENTS
19.7 APPLIED STEM CELL
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENT
19.8 ADDGENE
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 BIOVISION INC.
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENT
19.1 CELLECTA, INC
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENTS
19.11 CAS TAG BIOSCIENCES
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENT
19.12 GENECOPOEIA, INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 PRODUCT PORTFOLIO
19.12.3 RECENT DEVELOPMENT
19.13 HORIZON DISCOVERY LTD
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 HERA BIOLABS
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 NEW ENGLAND BIOLABS
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENTS
19.16 ORIGENE TECHNOLOGIES, INC.
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
19.17 SYNTHEGO
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 TAKARA BIO INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENT
19.19 TOOLGEN, INC.
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
표 목록
TABLE 1 PIPELINE ANALYSIS FOR NORTH AMERICA CRISPR GENE THERAPEUTICS
TABLE 2 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA CLASS-1 MULTIPLE EFFECTOR PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA AGRICULTURAL APPLICATIONS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA DRUG DISCOVERYIN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA OTHERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA CRRNA IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA CAS ENZYME IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA PRE-AMPLIFICATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA PRE-AMPLIFICATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA SAMPLE PREPARATION IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA SENSING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA SENSING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA BIOTECHNOLOGY COMPANIES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA ACADEMIC AND RESEARCH INSTITUTES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA DIAGNOSTIC CENTERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA HOSPITALS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA DIRECT TENDER IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA RETAIL SALES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 53 NORTH AMERICA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 54 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 57 U.S. CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 59 U.S. PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 U.S. ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 61 U.S. HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 62 U.S. PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 63 U.S. SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 65 U.S. GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 66 U.S. BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 68 U.S. PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 69 U.S. SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 70 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 71 U.S. CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 73 CANADA CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 75 CANADA PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 CANADA ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 77 CANADA HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 78 CANADA PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 79 CANADA SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 81 CANADA GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 82 CANADA BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 83 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 84 CANADA PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 85 CANADA SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 86 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 87 CANADA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 88 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 89 MEXICO CLASS-2 SINGLE CRRNA-BINDING PROTEIN IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 90 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCTS AND SERVICES, 2020-2029 (USD MILLION)
TABLE 91 MEXICO PRODUCTS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 MEXICO ASSAY KITS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 93 MEXICO HDR BLOCKERS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 94 MEXICO PROTEINS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 95 MEXICO SERVICES IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 97 MEXICO GENOME ENGINEERING IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 98 MEXICO BIOMEDICAL DIAGNOSTICS IN CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 99 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 100 MEXICO PRE-AMPLIFICATION IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 101 MEXICO SENSING IN GENE DETECTION AND DIAGNOSTIC MARKET, BY WORKFLOW, 2020-2029 (USD MILLION)
TABLE 102 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 103 MEXICO CRISPR GENE DETECTION AND DIAGNOSTIC MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: DBMR POSITION GRID
FIGURE 8 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: END USER COVERAGE GRID
FIGURE 10 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN TECHNOLOGICAL ADVANCEMENTS IN CRISPR DIAGNOSTICS, AND GOVERNMENT FUNDING FOR THE DEVELOPMENT OF CRISPR DETECTION KITS ARE EXPECTED TO DRIVE THE NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET FROM 2022 TO 2029
FIGURE 13 CLASS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET FROM 2022 & 2029
FIGURE 14 NORTH AMERICA CRISPR GENE PATENT SCENARIO, BY APPLICATION
FIGURE 15 CRISPR PATENT LANDSCAPE AND NUMBER OF APPLICATIONS OF NEW PATENT FAMILIES FILED WORLDWIDE, 2001 TO 2019
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET
FIGURE 17 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020
FIGURE 18 PREVALENCE OF HUNTINGTON’S DISEASE IN 2019
FIGURE 19 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, 2021
FIGURE 20 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, 2022-2029 (USD MILLION)
FIGURE 21 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, CAGR (2022-2029)
FIGURE 22 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS, LIFELINE CURVE
FIGURE 23 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2021
FIGURE 24 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, 2022-2029 (USD MILLION)
FIGURE 25 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, CAGR (2022-2029)
FIGURE 26 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY PRODUCTS AND SERVICES, LIFELINE CURVE
FIGURE 27 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, 2021
FIGURE 28 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 29 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 30 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, 2021
FIGURE 32 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, 2022-2029 (USD MILLION)
FIGURE 33 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, CAGR (2022-2029)
FIGURE 34 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY WORKFLOW, LIFELINE CURVE
FIGURE 35 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, 2021
FIGURE 36 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 37 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 41 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: SNAPSHOT (2021)
FIGURE 44 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2021)
FIGURE 45 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: BY CLASS (2022-2029)
FIGURE 48 NORTH AMERICA CRISPR GENE DETECTION AND DIAGNOSTIC MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
